Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration.
BACKGROUND
Sustained-release bupropion is commonly used for the symptomatic relief of depressive illness and as an adjuvant in smoking cessation therapy.


OBJECTIVE
To report a case of bupropion-induced drug rash with eosinophilia and systemic symptoms syndrome, including acute hepatitis, obstructive lung disease, and myositis.


METHODS
After the patient discontinued use of bupropion, serologic tests, muscle biopsies, pulmonary function tests, a chest x-ray examination, venous Doppler ultrasounds, and an electrocardiogram were performed.


RESULTS
On discontinuation of bupropion and prolonged systemic corticosteroid therapy, there was complete resolution of symptoms.


CONCLUSIONS
To our knowledge, this is the first reported case of drug rash with eosinophilia and systemic symptoms syndrome induced by bupropion therapy. We report this case to notify clinicians of the potential serious multisystem complications that can occur with sustained-release bupropion therapy.
Bagshaw
Sean M
SM
Department of Medicine, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada.
Cload
Bruce
B
Gilmour
Janet
J
Leung
Stephen T
ST
Bowen
Thomas J
TJ
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D002170:Canada; D004802:Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D006505:Hepatitis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D008297:Male; D009220:Myositis / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D010679:Philippines / Q000208:ethnology; D011239:Prednisolone / Q000627:therapeutic use; D016540:Smoking Cessation; D013577:Syndrome
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D011239:Prednisolone